AstraZeneca's Brilinta rolls out in India
The Indian subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched its patented antiplatelet drug Brilinta (ticagrelor), used to prevent heart attack, after receiving approval from the Drug Controller General of India (DCGI).
Based on the New Drug Advisory Committee's (NDAC) recommendations, the DCGI granted approval in May 2012 for marketing Brilinta tablets in India, the company said in a statement reported by the Economic Times of India.
The statement did not give the price of the drug. Commenting on the development AstraZeneca Pharma India vice president medical and regulatory affairs Paurus Irani said: "With over 40 lakh people affected by ACS in India each year, Brilinta gives cardiologists a new and effective treatment to help reduce the rate of heart attack and cardiovascular deaths in these patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze